Epidemiology, Treatment Outcomes and Costs of Treating Hepatitis C in Routine Care – Results from a Large Multicenter Trial

Abstract

A341 above treatments and with the following endpoints: Sustained Virological Response (SVR), discontinuation of all medications (overall/due to Adverse Events (AE)), and incidence of anemia, rash (all grades) and pruritus-common adverse events of cHCV treatment. A Bayesian NMA was performed for all endpoints, assuming fixed study effects. Unpublished SMV studies meeting the inclusion criteria were obtained. Results: Three studies met the inclusion criteria: 2 phase III RCTs (SMV n= 183; TVR n= 189), and 1 SMV phase IIb RCT (n= 92). Baseline characteristics were generally comparable for all studies. SMV shows a higher odds ratio (OR) of achieving SVR versus TVR (OR 1.68 (0.66-4.26)). SMV shows a lower OR of discontinuation: overall 0.35 (0.12-1.00) and due to AEs 0.87 (0.23-3.34) versus TVR. SMV shows a lower OR of experiencing anemia 0.20 (0.07-0.56) and rash 0.42 (0.17-0.99) but a higher OR of experiencing pruritus 1.26 (0.46-3.47) versus TVR. The main limitation of this study is the small number of trials included in the analysis. ConClusions: In this indirect comparison, SMV, in combination with PegIFN/RBV, showed a favourable risk-benefit profile compared to TVR with PegIFN/RBV in Japanese treatment-naïve Hepatitis C infected patients.

Predicting the Impact of Adverse Events and Treatment Duration on Medical Resource Utilization-Related Costs in Hepatitis C Genotype 1 Treatment-Naïve Patients Receiving Antiviral Therapy

“…The analyses performed here excluded the costs of antiviral and co-medications, which typically constitute the largest part of the total treatment costs for HCV patients [ 34 , 35 ]. The reason for this was that the first aim of this study was to identify patient and treatment characteristics that would influence MRU—and thus the total cost of care—so that these could be better managed, as in other therapeutic areas, such as oncology, diabetes and human immunodeficiency virus (HIV) infection [ 36 – 38 ].…”

“…The MRU-related costs in our study were within the ranges of treatment costs previously published. In the German context, the costs for outpatient visits were €355 (£293), which represent about 2 % of the total treatment cost for HCV patients [ 34 , 35 , 39 ]. Athanasakis et al [ 40 ] estimated the annual cost per patient for patients with a METAVIR score of F0–F3 to be €643 (£530), excluding the cost of medications.…”